Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P02746
UPID:
C1QB_HUMAN
Alternative names:
-
Alternative UPACC:
P02746; Q5T959; Q96H17
Background:
Complement C1q subcomponent subunit B plays a pivotal role in the immune system as part of the C1 complex, which is the first component of the serum complement system. It functions by associating with C1r and C1s proenzymes, facilitating the activation of the complement system upon interaction with immune complexes.
Therapeutic significance:
C1q deficiency 2, a disorder resulting from impaired activation of the complement classical pathway, highlights the critical role of Complement C1q subcomponent subunit B. This condition underscores the protein's potential as a target for therapeutic intervention in immune complex diseases, including systemic lupus erythematosus and glomerulonephritis.